What’s new about the first malaria treatment for babies?

WHO prequalification of first malaria drug for babies

A “major public health milestone” has been reached with WHO prequalification of Coartem Baby, described as the first malaria treatment for infants. The key practical change is that newborns and very young babies can be treated with a formulation intended for their age group rather than using medication designed for older children.

That matters because dosing and safety considerations differ sharply for babies. Using an adult or older-child formulation can create complications—clinicians may have to rely on off-label adjustments and the risk of incorrect dosing is higher. A prequalified, age-appropriate medicine supports standardized procurement and treatment protocols, which is especially important where healthcare resources are limited.

The story links the milestone to broader global health systems: WHO prequalification helps national programs and partner organizations identify quality-assured products that meet international standards. It can also accelerate access when countries are deciding which therapies to stock for pediatric malaria care.

Even with prequalification, outcomes depend on implementation—such as how quickly supply chains deliver the drug to clinics and how consistently healthcare workers administer it. But the central development highlighted here is that infants now have an approved, quality-assured antimalarial option specifically for their age, which strengthens early treatment and potentially improves survival rates for the youngest patients.

Overall, the update signals that malaria control efforts can become more age-appropriate, reducing the need for less suitable alternatives for infants and supporting better health equity in early childhood.